股票简称：禾元生物 股票代码：688765 武汉禾元生物科技股份有限公司 Wuhan Healthgen Biotechnology Corp. （武汉东湖新技术开发区神墩五路 268 号） 首次公开发行股票 科创板上市公告书 保荐人（联席主承销商） 中国（上海）自由贸易试验区商城路 618 号 联席主承销商 北京市朝阳区安立路 66 号 4 号楼 二〇二五年十月二十四日 武汉禾元生物科技股份有限公司 上市公告书 特别提示 武汉禾元生物科技股份有限公司（以下简称"禾元生物"、"发行人"、"公 司"、"本公司"）股票将于 2025 年 10 月 28 日在上海证券交易所科创板上市。 根据《上海证券交易所科创板上市公司自律监管指引第 5 号——科创成长 层》，上市时未盈利的科创板公司，自上市之日起纳入科创成长层。截至本公告 披露日，禾元生物尚未盈利，自上市之日起将纳入科创成长层。 普通投资者参与科创成长层股票或者存托凭证交易的，应当符合科创板投资 者适当性管理的要求，并按照上海证券交易所有关规定，在首次参与交易前以纸 面或者电子形式签署《科创成长层风险揭示书》，由证券公司充分告知相关风险。 本公司提醒投资者应充分 ...

Core Points - The restructuring protein concept declined by 1.15%, ranking among the top declines in concept sectors as of the market close on October 23 [1] - Within the restructuring protein sector, major declines were observed in companies such as Haitai Biological, Maiwei Biological, and Yipinhong, while 14 stocks experienced price increases, with *ST Suwu, *ST Wanfang, and Kefu Medical leading the gains at 5.21%, 4.99%, and 2.90% respectively [1] Market Performance - The top-performing concept sectors today included Shenzhen State-Owned Enterprise Reform with a rise of 6.62%, while the restructuring protein sector faced a decline of 1.15% [2] - The restructuring protein sector saw a net outflow of 476 million yuan, with 37 stocks experiencing net outflows, and 6 stocks seeing outflows exceeding 30 million yuan [2] - Maiwei Biological led the net outflow with 69.48 million yuan, followed by Hualan Biological, BeiDa Pharmaceutical, and Zhifei Biological with outflows of 66.43 million yuan, 54.42 million yuan, and 33.70 million yuan respectively [2] Stock Performance - The top stocks with significant net outflows in the restructuring protein sector included: - Maiwei Biological: -5.53% with a turnover rate of 7.46% and a net outflow of 69.48 million yuan - Hualan Biological: -1.41% with a turnover rate of 1.37% and a net outflow of 66.43 million yuan - BeiDa Pharmaceutical: -3.26% with a turnover rate of 1.78% and a net outflow of 54.42 million yuan [3] - Conversely, the stocks with notable net inflows included: - SanSheng Guojian: +0.67% with a net inflow of 40.98 million yuan - Baipu Sais: +0.17% with a net inflow of 12.23 million yuan - Huiyu Pharmaceutical: +2.96% with a net inflow of 5.71 million yuan [4]

Market Performance - The Hang Seng Healthcare Index decreased by 2.71% as of October 23, 2025, with mixed performance among constituent stocks [2] - The Hang Seng Medical ETF (513060) fell by 2.41%, with a latest price of 0.65 CNY, but has seen a 3.42% increase over the past three months [2] - The Hong Kong Stock Connect Innovative Drug Selection Index dropped by 3.70%, with the Hong Kong Innovative Drug Selection ETF (520690) down by 3.26% [4][5] - The CSI Pharmaceutical 50 Index declined by 0.95%, while the Pharmaceutical 50 ETF (159838) decreased by 0.96% [6] Liquidity and Trading Activity - The Hang Seng Medical ETF had a turnover of 11.25% and a trading volume of 763 million CNY, indicating active market participation [2] - The Hong Kong Innovative Drug Selection ETF recorded a turnover of 21.44% with a trading volume of approximately 98.5 million CNY [5] - The Pharmaceutical 50 ETF had a turnover of 1.67% and a trading volume of 2.71 million CNY [6] Key Events and Trends - The flu season has started early, leading to a rise in flu-related stocks, with companies like Hendi Pharmaceutical and Duori Pharmaceutical seeing significant gains [7] - The ongoing ESMO (European Society for Medical Oncology) conference has heightened interest in Chinese pharmaceutical companies, showcasing clinical data from firms like Heng Rui Pharmaceutical and Ke Long Bo Tai [7] - The collaboration between Sinopharm and Takeda is expected to enhance foreign investment confidence in Chinese innovative drug assets [7] Industry Insights - The Chinese innovative drug sector is accelerating its international presence, with 135 licensing-out transactions recorded from January to October 17, 2025, totaling over 102.9 billion USD [7] - The ESMO conference highlighted 23 LBA studies led by Chinese scholars, demonstrating the global competitiveness of China's innovative drug pipeline [7] - The aging population is increasing the demand for chronic disease treatments, while the optimization of the medical insurance payment system and AI technology applications are injecting new vitality into the industry [8] ETF Overview - The Hang Seng Medical ETF has a current scale of 6.865 billion CNY, ranking in the top third among comparable funds [8] - The Hong Kong Innovative Drug Selection ETF reached a new high with a scale of 468 million CNY [10] - The Pharmaceutical 50 ETF tracks the top 50 pharmaceutical companies in China, with the top ten stocks accounting for 59.46% of the index [11]

资料显示，贝达药业股份有限公司位于浙江省杭州市临平区经济技术开发区兴中路355号,香港铜锣湾希 慎道33号利园1期19楼1919室，成立日期2003年1月7日，上市日期2016年11月7日，公司主营业务涉及药 品的研发、生产和销售。主营业务收入构成为：药品销售99.10%，其他(补充)0.90%。 贝达药业所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：眼科概念、抗癌治癌、 抗癌药物、创新药、生物医药等。 10月23日，贝达药业盘中下跌2.03%，截至09:47，报57.08元/股，成交3774.79万元，换手率0.16%，总 市值240.15亿元。 资金流向方面，主力资金净流出442.88万元，特大单买入0.00元，占比0.00%，卖出218.89万元，占比 5.80%；大单买入502.80万元，占比13.32%，卖出726.80万元，占比19.25%。 贝达药业今年以来股价涨6.23%，近5个交易日跌2.94%，近20日跌16.83%，近60日跌8.99%。 分红方面，贝达药业A股上市后累计派现6.69亿元。近三年，累计派现1.84亿元。 机构持仓方面，截止2025年6月30日，贝达药业十 ...

Group 1 - On October 22, 2023, Benda Pharmaceutical conducted a block trade of 95,800 shares, with a transaction amount of 4.4844 million yuan, accounting for 1.28% of the total trading volume for the day [1][2] - The transaction price was 46.81 yuan per share, which represents a discount of 19.65% compared to the market closing price of 58.26 yuan [1][2]

Group 1: Key Recommendations - The report highlights the strong performance of Cambricon (688256), with a year-on-year revenue increase of 2386.38% to 4.607 billion yuan and a net profit increase of 321.49% to 1.605 billion yuan for the first three quarters of 2025 [5][6][8] - The report emphasizes the significant growth in revenue and net profit driven by the cloud AI chip products, particularly the Siyuan 590, which is expected to benefit from increasing demand and domestic market penetration [6][8] - The company has completed a 3.985 billion yuan private placement, enhancing its financial stability and providing strong funding for future research and development [8][10] Group 2: Industry Insights - The biopharmaceutical sector experienced a decline of 2.48% in the week of October 13-17, 2025, underperforming the CSI 300 index by 0.26 percentage points, with a current PE valuation of 30.71 times [12][13] - The ESMO 2025 conference showcased significant clinical research advancements, with 448 abstracts from Chinese companies, highlighting the growing influence of Chinese pharmaceutical firms in the global market [13][14] - The report suggests focusing on leading companies with promising data in the innovative drug sector, as well as opportunities in CXO, medical devices, and healthcare services [14][15]

Core Insights - Riltide Medicines has completed a seed round financing of several million RMB, led by Newerly Capital and followed by Qingtan Investment, to advance its core pipeline in preclinical research and develop an AI interactive molecular design platform [3][4] - The company focuses on the development of innovative oral small molecule drugs targeting autoimmune diseases such as systemic lupus erythematosus and inflammatory bowel disease [3][4] - The founder and CEO, Long Wei, has nearly 20 years of experience in drug research and management, previously holding senior positions in other pharmaceutical companies [3] Company Strategy - Riltide Medicines aims to leverage advancements in AI technology to enhance drug discovery processes, particularly in the field of oral small molecule drugs, which are becoming increasingly important in autoimmune disease treatment [4][5] - The company has developed its own EnCore AI interactive design platform to accelerate the discovery of lead compounds and improve molecular optimization efficiency [4][5] Market Potential - Investors express confidence in Riltide Medicines' strategic direction in developing oral small molecule drugs for autoimmune diseases, highlighting the significant demand potential in this area [6] - The integration of AI in drug design is seen as a key factor that could enable the company to explore globally competitive product projects [6]

Investment Rating - The industry investment rating is "Overweight" indicating that the industry index is expected to outperform the CSI 300 index by 10% or more over the next six months [37]. Core Insights - The pharmaceutical and biotechnology sector experienced an overall decline of 2.48% from October 13 to October 17, 2025, ranking 16th among 31 industries and underperforming the CSI 300 index by 0.26 percentage points. The current PE valuation for the sector is 30.71 times, which is at a historically low level, with a valuation premium of 131% compared to the CSI 300 index [3][13][24]. - The 2025 European Society for Medical Oncology (ESMO) conference showcased numerous cutting-edge clinical research results, with significant contributions from Chinese companies. The conference highlighted key studies in various cancer types, including breast cancer and lung cancer, which may reshape clinical treatment paradigms [4][33]. Summary by Sections Market Performance - The pharmaceutical and biotechnology sector's overall decline of 2.48% places it 16th among 31 industries, underperforming the CSI 300 index by 0.26 percentage points. The only sub-sector that increased was Traditional Chinese Medicine II, which rose by 0.38%. Other sub-sectors, including pharmaceutical commerce, chemical pharmaceuticals, and medical devices, saw declines of 0.89%, 1.78%, and 3.19%, respectively [3][13][24]. Industry News - The ESMO 2025 conference, held from October 17 to 21 in Berlin, presented numerous groundbreaking clinical research findings, attracting global experts. Key studies included the T-DXd "Gemini" studies and updates on the FLAURA2 study for EGFR-mutant advanced NSCLC, among others. A total of 2,929 abstracts were presented, with 448 from Chinese companies, marking a significant platform for showcasing China's innovative pharmaceutical capabilities [4][33]. Investment Recommendations - The report suggests focusing on leading companies in the innovative drug sector that have demonstrated strong data, as well as platform companies with cutting-edge technologies. It also recommends exploring investment opportunities in CXO, medical devices, and healthcare services sectors [5][35]. - Recommended stock picks include Kelun Pharmaceutical, Zhongsheng Pharmaceutical, Betta Pharmaceuticals, Kaili Medical, Pumen Technology, and Huaxia Eye Hospital. Stocks to watch include Rongchang Biopharmaceutical, Teva Biopharmaceutical, Ganred Pharmaceutical, Yifeng Pharmacy, Baipusais, and Lingrui Pharmaceutical [7][35].

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" and the rating has been maintained [1] Core Insights - The pharmaceutical and biotechnology industry index declined by 3.65% during the reporting period, ranking 21st among 31 primary industries, underperforming the CSI 300 index which fell by 2.73% [4][16] - The valuation of the pharmaceutical and biotechnology industry as of October 17, 2025, is a PE (TTM overall method, excluding negative values) of 30.08x, down from 31.23x in the previous period, indicating a downward trend and below the average [4][21] - Key sub-industries include vaccines (55.76x), hospitals (39.64x), and medical devices (38.84x), with the lowest valuation in pharmaceutical circulation (14.29x) [4][21] - The report highlights significant innovations presented at the 2025 ESMO conference, indicating a shift in global oncology drug development from "single-agent breakthroughs" to "combination therapy strategies" [6][8] - The newly released regulations by the State Council aim to standardize clinical research pathways, promoting innovation while ensuring safety [7][25][26] Industry Overview - The report notes that 26 listed companies in the pharmaceutical and biotechnology sector experienced a net reduction in shareholder holdings amounting to 501 million yuan, while 4 companies increased their holdings by 519 million yuan [4] - The report emphasizes the importance of monitoring third-quarter earnings to validate the fundamentals of companies, particularly those with innovative product launches and significant performance improvements [8] Important Industry News - The approval of the first domestic PDE4 inhibitor by He Mei Pharmaceutical marks a significant milestone in the industry [6][34] - The approval of a new indication for GSK's recombinant shingles vaccine expands its application to adults at increased risk due to immunodeficiency [6][36] - The U.S. Senate passed a revised version of the Biosecurity Act, which continues to impose restrictions on certain Chinese biotechnology companies [6][44] - The collaboration between Bai Li Tian Heng and BMS on the iza-bren project has reached a milestone, triggering a payment of 250 million USD [6][47] - The IPO of Xuan Zhu Biotechnology on the Hong Kong Stock Exchange saw a significant oversubscription and a substantial increase in share price during the dark trading period [6][49]

Core Viewpoint - He Yuan Bio (688765.SH) has launched its IPO on the Sci-Tech Innovation Board with an issue price of 29.06 yuan per share, focusing on the production of recombinant human serum albumin using rice as a production platform, which is expected to alleviate the supply shortage of blood products in China [1][2][3]. Company Overview - He Yuan Bio specializes in biopharmaceuticals, specifically in the production of recombinant human serum albumin by implanting human serum albumin genes into rice, allowing for large-scale synthesis and purification from rice [1][2]. - The company has developed a third-generation technology platform that achieves an expression level of 20-30g/kg of human serum albumin in brown rice, addressing the historical supply issues of this critical blood product [1][6]. Market Potential - Human serum albumin is the most widely used blood product in clinical settings in China, with no equivalent alternatives available, indicating a strong market demand [2][3]. - The approval of He Yuan Bio's recombinant human serum albumin is expected to mirror the market penetration path of early recombinant insulin companies, potentially leading to rapid sales growth and strong cash flow for the company [2][3]. Funding and Investment - The company aims to raise 2.4 billion yuan through its IPO, with plans to invest 1.658 billion yuan in the construction of an industrialization base for recombinant human serum albumin, 642 million yuan in new drug research and development, and 100 million yuan to supplement working capital [2][7][8]. Research and Development - He Yuan Bio has invested significantly in R&D, with expenditures of 110 million yuan, 159 million yuan, and 117 million yuan from 2022 to 2024, totaling 386 million yuan over three years [5]. - The company holds 21 domestic and 62 international invention patents, with 17 patents applicable to its main business and capable of industrialization [5]. Production Capabilities - The company has established a rice endosperm cell bioreactor technology system, which includes a high-efficiency recombinant protein expression platform and a purification technology platform, facilitating large-scale and cost-effective production [6]. - He Yuan Bio has built a commercial-scale production line capable of producing 10 tons of OsrHSA raw liquid annually and is expanding to a new production line with a capacity of 120 tons [8]. Commercialization Strategy - Following the approval of its product, He Yuan Bio has initiated sales through its own team and partnerships with major distributors, establishing a sales network across over 30 provinces [7][8]. - The company has multiple drugs in development, with several at various stages of clinical trials, laying the groundwork for future commercialization [8][9].